Video

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Following stem cell transplant, maintenance therapy with lenalidomide (Revlimid) is the standard of care, says Berdeja. Although data from the PURPOSE trial have suggested that bortezomib (Velcade) can also be used in select patients, Bordeja cautions that the arm that received bortezomib maintenance also received bortezomib at the time of induction. Physicians are unsure of whether the benefit was due to the patient’s exposure to the proteasome inhibitor (PI) during induction, or their exposure to the PI during maintenance.

At the 2018 ASH Annual Meeting, a study was presented on maintenance with ixazomib (Ninlaro), adds Berdeja. For this trial, investigators set out to answer the question of whether or not a PI as maintenance therapy can improve progression-free survival and overall survival. Although the study follow-up is relatively short, there seems to be an improvement in PFS with maintenance ixazomib, says Bordeja, but whether or not it is superior to lenalidomide maintenance remains to be seen.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity